<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="16118">Berberine</z:chebi> (Ber) 20 mg.kg-1.d-1 for 1, 3, or 5 d inhibited platelet aggregation induced by <z:chebi fb="13" ids="16761">ADP</z:chebi>, <z:chebi fb="0" ids="15843">arachidonic acid</z:chebi> (AA) and collagen (Coll) in rats with 24 h reversible middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO), and the platelet adhesiveness was inhibited as well </plain></SENT>
<SENT sid="1" pm="."><plain>Using radioimmunoassay method, the <z:chebi fb="0" ids="28728">thromboxane B2</z:chebi>(<z:chebi fb="0" ids="28728">TXB2</z:chebi>) and 6-keto-<z:chebi fb="0" ids="28852">prostaglandin F1 alpha</z:chebi> (6-keto-<z:chebi fb="0" ids="28852">PGF1 alpha</z:chebi>) contents in rat plasma were measured 24 h after MCAO </plain></SENT>
<SENT sid="2" pm="."><plain>The results indicate that the <z:chebi fb="0" ids="28728">TXB2</z:chebi> levels after drug treatment were lower than those in <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> control rats, but the 6-keto-<z:chebi fb="0" ids="28852">PGF1 alpha</z:chebi> levels showed no obvious difference between the two groups </plain></SENT>
<SENT sid="3" pm="."><plain>The same dose of Ber was also shown to inhibit <z:mp ids='MP_0005048'>thrombosis</z:mp> formation </plain></SENT>
<SENT sid="4" pm="."><plain>This suggests that the decline of platelet aggregation and decrease of <z:chebi fb="0" ids="28728">TXB2</z:chebi> content may be one of the important factors involved in the anti-<z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> effect of Ber </plain></SENT>
</text></document>